Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(Epavudine; L-Thymidine; NV 02B)
Telbivudine Chemical Structure
|Product name: Telbivudine|
|Cat. No.: HY-B0017|
Telbivudine, a specific inhibitor of hepatitis B virus (HBV) replication, is an antiviral drug used in the treatment of hepatitis B infection.
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. Telbivudine is a synthetic thymidine nucleoside analogue, it is the L-isomer of thymidine. It is taken once daily.
Telbivudine is a potent antiviral that provides effective and sustained viral suppression in patients with compensated CHB. In clinical trials, treatment outcomes were improved significantly more with telbivudine 600?mg once daily than with lamivudine 100?mg or adefovir 10?mg once daily, and telbivudine-treated patients had significantly less viral resistance than lamivudine-treated patients. Telbivudine is associated with a medium genetic barrier to resistance and, as patients with undetectable HBV DNA levels have significantly improved outcomes, it is recommended that HBV DNA levels are monitored at week 24 (and 6 monthly thereafter), with the addition of a nucleoside/nucleotide analogue without cross resistance (such as adefovir dipivoxil) if viraemia is present to reduce the risk of resistance (Roadmap concept). Telbivudine was generally well tolerated in clinical trials for periods of up to 4 years, and has a similar tolerability profile to that of lamivudine.
|M.Wt||242.23||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||4.1283 mL||20.6415 mL||41.2831 mL|
|5 mM||0.8257 mL||4.1283 mL||8.2566 mL|
|10 mM||0.4128 mL||2.0642 mL||4.1283 mL|
Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.
Bicyclol(SY 801) is a anti-hepatitis drug.
Clevudine is an antiviral drug for the treatment of hepatitis B.
Lagociclovir(MIV-210) is a prodrug of 3(acute)-fluoro-2(acute),3(acute)-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV.
Merimepodiba(VX-497) is a novel noncompetitive inhibitor of IMPDH(Inosine monophosphate dehydrogenase).
Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 (mu)M.
Oxethazaine is a topical anesthetic, in preventing acid-induced esophageal pain.